Lab
Millennium Health, LLC
Millennium Health, LLC was paid $579.29M by Medicaid between Jan 2018 and Dec 2024, across 72 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 26% of everything it billed.
33Billing provider infoMILLENNIUM HEALTH, LLC
SAN DIEGO, CA 92127
SAN DIEGO, CA 92127
33aNPI1497933162assigned 02/05/2008
33bProvider typeClinical Medical Laboratory
28Total paid$579.29M
24GClaims30,684,871
24DCodes billed72
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#3 of 561
Median peer was paid$222K
This provider vs. median2,610×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official THOMAS, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,079,459 | $71.06M | |
| 2019 | 8,371,034 | $82.35M | |
| 2020 | 7,209,590 | $65.53M | |
| 2021 | 2,397,548 | $64.78M | |
| 2022 | 2,754,195 | $83.46M | |
| 2023 | 2,139,251 | $113.00M | |
| 2024incomplete | 1,733,794 | $99.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 26% | 1,813,365 | 947,184 | $152.24M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 22% | 993,030 | 522,631 | $130.03M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 16% | 2,943,166 | 1,452,297 | $90.51M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 13% | 1,093,441 | 617,117 | $76.60M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 7.5% | 898,069 | 452,131 | $43.33M |
| 80321 | <1% | 865,214 | 405,766 | $4.45M | |
| 80361 | <1% | 947,271 | 462,300 | $4.08M | |
| 80348 | <1% | 918,527 | 443,776 | $3.90M | |
| 80346 | <1% | 954,211 | 465,693 | $3.84M | |
| 83992 | <1% | 648,612 | 327,600 | $3.67M | |
| 80356 | <1% | 964,259 | 465,955 | $3.49M | |
| 80365 | <1% | 962,039 | 471,256 | $3.47M |
60 more codes
| 80373 | <1% | 843,938 | $3.45M | |
| 80354 | <1% | 957,688 | $3.39M | |
| 80353 | <1% | 975,901 | $3.26M | |
| 80349 | <1% | 919,883 | $3.21M | |
| 80358 | <1% | 962,657 | $3.13M | |
| 80372 | <1% | 714,639 | $2.89M | |
| 80323 | <1% | 585,628 | $2.83M | |
| 80359 | <1% | 763,497 | $2.68M | |
| 80345 | <1% | 702,787 | $2.51M | |
| 80352 | <1% | 555,709 | $2.45M | |
| 80355 | <1% | 724,992 | $2.40M | |
| 80369 | <1% | 554,546 | $2.27M | |
| 80360 | <1% | 626,868 | $2.09M | |
| 80363 | <1% | 463,926 | $1.91M | |
| 80324 | <1% | 486,841 | $1.82M | |
| 80368 | <1% | 458,652 | $1.77M | |
| 80366 | <1% | 466,183 | $1.69M | |
| 80371 | <1% | 459,732 | $1.67M | |
| 80325 | <1% | 483,566 | $1.53M | |
| 81226 | <1% | 12,043 | $1.41M | |
| 80362 | <1% | 364,454 | $1.37M | |
| 80357 | <1% | 314,949 | $1.17M | |
| 81225 | <1% | 11,948 | $899K | |
| 84311 | <1% | 553,381 | $894K | |
| 80336 | <1% | 164,224 | $689K | |
| 80343 | <1% | 143,133 | $689K | |
| 82570 | <1% | 577,161 | $674K | |
| 80338 | <1% | 182,506 | $663K | |
| 80333 | <1% | 136,218 | $532K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 42,139 | $454K |
| 83986 | <1% | 576,773 | $450K | |
| 81381 | <1% | 7,529 | $423K | |
| 80342 | <1% | 72,667 | $416K | |
| 81003 | <1% | 575,263 | $292K | |
| 81230 | <1% | 6,382 | $243K | |
| 81231 | <1% | 6,352 | $238K | |
| 80335 | <1% | 67,136 | $176K | |
| 81227 | <1% | 4,269 | $170K | |
| 81291 | <1% | 11,777 | $164K | |
| 80364 | <1% | 33,074 | $150K | |
| 80375 | <1% | 32,635 | $142K | |
| 80332 | <1% | 32,436 | $113K | |
| 80374 | <1% | 23,888 | $107K | |
| 81355 | <1% | 3,708 | $67K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,459 | $58K |
| 80339 | <1% | 14,483 | $35K | |
| 87481 | <1% | 766 | $11K | |
| 87551 | <1% | 292 | $8K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 251 | $5K |
| 87640 | <1% | 251 | $5K | |
| 87500 | <1% | 250 | $4K | |
| 87653 | <1% | 237 | $4K | |
| 80326 | <1% | 949 | $3K | |
| 80370 | <1% | 639 | $2K | |
| 80337 | <1% | 74 | $304.90 | |
| 80334 | <1% | 111 | $304.84 | |
| 80344 | <1% | 97 | $294.58 | |
| G0479 | Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, tof, maldi, ldtd, desi, dart, ghpc, gc mass spectrometry), includes sample validation when performed, per date of service | <1% | 39 | $198.50 |
| 99080 | 0% | 61 | $0.00 | |
| 80301 | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHOMAS, ROBERT (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Lehigh Valley Hospital | Allentown, PA | $64.40M |
| Lehigh Valley Hospital Pocono | East Stroudsburg, PA | $11.90M |
| Lehigh Valley Hospital Hazleton | Hazleton, PA | $11.69M |
| Lehigh Valley Hospital | Allentown, PA | $10.00M |
| Lehigh Valley Hospital - Schuylkill | Pottsville, PA | $6.83M |
| Lehigh Valley Hospital- Pocono | Dickson City, PA | $3.75M |
| Lehigh Valley Hospital | Allentown, PA | $2.90M |
| Lehigh Valley Hospital | Allentown, PA | $1.95M |
| Lehigh Valley Hospital, INC | Allentown, PA | $1.85M |
| Lehigh Valley Hospital | Allentown, PA | $1.40M |
| Lehigh Valley Hospital - Schuylkill | Saint Clair, PA | $744K |
| Maryland Wound & Amputation Prevention, LLC | Lutherville, MD | $399K |
| Robert L Thomas MD FCCP LLC | Walterboro, SC | $253K |
| A-One Home Health Services, LLC | Everett, WA | $236K |
| Avamere Home Health Care, LLC | Bellingham, WA | $234K |
| Lehigh Valley Hospital Schuylkill | Pottsville, PA | $218K |
| Lehigh Valley Hospital Hazleton | Hazleton, PA | $193K |
| Prime Home Health, LLC | Federal Way, WA | $115K |
| Lehigh Valley Hospital | Allentown, PA | $70K |
| Northwest Hospice LLC | Tigard, OR | $33K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.